(Q29042159)

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

author name string

Francisco A. Bonilla

1

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

I. Leonard Bernstein

2

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

David A. Khan

3

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

Zuhair K. Ballas

4

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

Javier Chinen

5

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

Michael M. Frank

6

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

Lisa J. Kobrynski

7

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

Arnold I. Levinson

8

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

Bruce Mazer

9

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

Robert P. Nelson

10

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

Jordan S. Orange

11

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

John M. Routes

12

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

William T. Shearer

13

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

Ricardo U. Sorensen

14

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

language of work or name

1 reference

May 2005

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

Annals of Allergy, Asthma & Immunology

27 March 2017

published in

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

volume

94

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

issue

5

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

page(s)

S1-S63

1 reference

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

Clinical guidelines: developing guidelines

27 March 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Primary immunodeficiency diseases in Norway

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Primary immunodeficiency diseases in Latin America: first report from eight countries participating in the LAGID. Latin American Group for Primary Immunodeficiency Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Primary immunodeficiency disorders: antibody deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Primary cellular immunodeficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Primary immunodeficiency diseases: an experimental model for molecular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Chronic granulomatous disease. Report on a national registry of 368 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Primary immunodeficiency diseases: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Clinical and laboratory evaluation of complement deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Diseases involving the T-cell receptor/CD3 complex

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

12. Primary immunodeficiency diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Primary immunodeficiency disorders in children: prompt diagnosis can lead to lifesaving treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

7. Rhinitis and sinusitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Relationships between atopy and bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Laterally hypertrophic adenoids as a contributing factor in otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Primary ciliary dyskinesia: diagnosis and standards of care

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Assessment of the child with recurrent chest infections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Diagnosis of immunodeficiency: clinical clues and diagnostic tests

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Role of complement in the development of autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Autoimmune manifestations of the Wiskott-Aldrich syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Common variable immunodeficiency: clinical and immunological features of 248 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

APECED mutations in the autoimmune regulator (AIRE) gene

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Screening for primary immunodeficiencies in the clinical immunology laboratory

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

24. Clinical and laboratory assessment of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Detection of X-linked lymphoproliferative disease using molecular and immunovirologic markers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Online Registry of Genetic and Clinical Immunodeficiency Diagnostic Laboratories, IDdiagnostics

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Severe phenotype of chronic granulomatous disease presenting in a female with a de novo mutation in gp91-phox and a non familial, extremely skewed X chromosome inactivation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Wiskott-Aldrich syndrome in a female with skewed X-chromosome inactivation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Wiskott-Aldrich syndrome in a female

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

CD40 ligand expression deficiency in a female carrier of the X-linked hyper-IgM syndrome as a result of X chromosome lyonization

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Diagnosis and carrier detection of chronic granulomatous disease in five families by flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

X-chromosome inactivation in the Wiskott-Aldrich syndrome: a marker for detection of the carrier state and identification of cell lineages expressing the gene defect

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Carrier identification in X-linked immunodeficiency diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Determination of carrier status for the Wiskott-Aldrich syndrome by flow cytometric analysis of Wiskott-Aldrich syndrome protein expression in peripheral blood mononuclear cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

X-linked agammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

X-linked agammaglobulinemia. A clinical and molecular analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Intravenous immunoglobulin treatment of immunodeficiency disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Human intravenous immunoglobulin in primary and secondary antibody deficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Consensus on diagnosis and management of primary antibody deficiencies. Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Open trial of intravenous immune serum globulin for chronic sinusitis in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A prospective, double-blind, placebo-controlled trial of i.v. immunoglobulin and trimethoprim-sulfamethoxazole in children with recurrent respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Antimicrobial prophylaxis for infants at risk for recurrent acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Randomized trial of the efficacy of trimethoprim-sulfamethoxazole and prednisone in preventing post-tympanostomy tube morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Defective antipneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Evaluating children with respiratory tract infections: the role of immunization with bacterial polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Follow-up of pediatric patients with recurrent infection and mild serologic immune abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

The clinical and economic consequences of nosocomial central venous catheter-related infection: are antimicrobial catheters useful?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Subcutaneous immunoglobulin replacement in primary immunodeficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Chronic sinusitis refractory to standard management in patients with humoral immunodeficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immunologic defects in patients with chronic recurrent sinusitis: diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

T-cell immune constitution after peripheral blood mononuclear cell transplantation in complete DiGeorge syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Bone marrow transplantation as treatment for X-linked immunodeficiency with hyper-IgM

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A historical review of bone marrow transplantation for immunodeficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immunologic reconstitution following bone marrow transplantation for X-linked hyper IgM syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Correction of the hyper-IgM syndrome after liver and bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Successful bone marrow transplantation in a child with X-linked hyper-IgM syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immunological reconstitution by allogeneic bone marrow transplantation in a child with the X-linked hyper-IgM syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Correction of complete interferon-gamma receptor 1 deficiency by bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Correction of neutropenia and hypogammaglobulinemia in X-linked hyper-IgM syndrome by allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Brief report: correction of X-linked hyper-IgM syndrome by allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

European experience of bone-marrow transplantation for severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Pretransfusion blood irradiation: clinical rationale and dosimetric considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immunopathogenic mechanisms of posttransfusion graft-vs-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Transfusion-transmitted diseases: risks, prevention and perspectives.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Inherited interleukin 12 deficiency in a child with bacille Calmette-Guérin and Salmonella enteritidis disseminated infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Polio vaccine virus-associated meningoencephalitis in an infant with transient hypogammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Live viral vaccines in patients with partial DiGeorge syndrome: clinical experience and cellular immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

1 reference

7 January 2021

The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Pulmonary abnormalities in patients with primary hypogammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Neutropenia in X-linked agammaglobulinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Encephalomyelitis in primary hypogammaglobulinaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Pneumocystis carinii pneumonia in an infant with X-linked agammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Poliovirus vaccination in an infant with hypogammaglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Ureaplasma urealyticum arthritis and bacteremia in agammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Regional Enteritis Associated with Enterovirus in a Patient with X-Linked Agammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Defects in early B-cell development: comparing the consequences of abnormalities in pre-BCR signaling in the human and the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutations in btk in patients with presumed X-linked agammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A mutation in Bruton's tyrosine kinase as a cause of selective anti-polysaccharide antibody deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Atypical X-linked agammaglobulinemia diagnosed in three adults

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

X linked agammaglobulinaemia with a 'leaky' phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A case of X-linked agammaglobulinemia diagnosed in adulthood

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Extreme variation in X-linked agammaglobulinemia phenotype in a three-generation family

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Detection of Bruton's tyrosine kinase mutations in hypogammaglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Assessment of male CVID patients for mutations in the Btk gene: how many have been misdiagnosed?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Gastric adenocarcinoma in a patient with X-linked agammaglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Chronic enteroviral meningoencephalitis in agammaglobulinemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Chronic enteroviral meningo-encephalitis in X-linked agammaglobulinaemia: favourable response to anti-enteroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Pleconaril: a novel antipicornaviral drug

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Lung transplantation in patients with x-linked agammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A human non-XLA immunodeficiency disease characterized by blockage of B cell development at an early proB cell stage

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutations in the mu heavy-chain gene in patients with agammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutations in Igalpha (CD79a) result in a complete block in B-cell development

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Novel Igalpha (CD79a) gene mutation in a Turkish patient with B cell-deficient agammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

An essential role for BLNK in human B cell development

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

LRRC8 involved in B cell development belongs to a novel family of leucine-rich repeat proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

ICOS deficiency in patients with common variable immunodeficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Variability of clinical and immunological phenotype in immunodeficiency-centromeric instability-facial anomalies syndrome. Report of two new patients and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Centromeric instability of chromosome 1 resulting in multibranched chromosomes, telomeric fusions, and "jumping translocations" of 1q in a human immunodeficiency virus-related non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

ICF syndrome (immunodeficiency, centromeric instability and facial anomalies): investigation of heterochromatin abnormalities and review of clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Primary immunodeficiency disorders in Sweden: Cases among children, 1974?1979

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Granulomatous disease in common variable immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Cytomegalovirus enteritis in common variable immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Clinical and immunologic analyses of 103 patients with common variable immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Non-hodgkin lymphoma in common variable immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Lymphoid interstitial pneumonitis associated with common variable hypogammaglobulinaemia treated with cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Idiopathic late-onset immunoglobulin deficiency. Clinical observations in 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Prospective study of cancer in patients with hypogammaglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Common variable immunodeficiency: clinical aspects and recent progress in identifying the immunological defect(s).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

IL-4 synergizes with IL-10 and anti-CD40 MoAbs to induce B-cell differentiation in patients with common variable immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immunodeficiency associated with loss of T4+ inducer T-cell function

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Uncoupling of T-Cell Antigen Receptor and Downstream Protein Tyrosine Kinases in Common Variable Immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Defective recruitment and activation of ZAP-70 in common variable immunodeficiency patients with T cell defects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Primary defect in CD8+ lymphocytes in the antibody deficiency disease (common variable immunodeficiency): abnormalities in intracellular production of interferon-gamma (IFN-gamma) in CD28+ ('cytotoxic') and CD28- ('suppressor') CD8+ subsets.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Infections in patients with immunodeficiency with thymoma (Good syndrome). Report of 5 cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Fatal varicella infection in a child associated with thymoma and immunodeficiency (Good's syndrome)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

What is Good's syndrome? Immunological abnormalities in patients with thymoma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

The heterogeneity of IgA deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Fine mapping of IGAD1 in IgA deficiency and common variable immunodeficiency: identification and characterization of haplotypes shared by affected members of 101 multiple-case families

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

IgA deficiency: what we should-or should not-be doing

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Gender, age and seasonal effects on IgA deficiency: a study of 7293 Caucasians

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Secondary hypogammaglobilinemia after use of carbamazepine: case report and review

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Reversible panhypogammaglobulinemia associated with phenytoin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Physiology of IgA and IgA deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

IgA deficiency: clinical correlates and responses to pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

The association of celiac disease, diabetes mellitus type 1, hypothyroidism, chronic liver disease, and selective IgA deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

The significance of IgG subclasses and mannan-binding lectin (MBL) for susceptibility to infection in apparently healthy adults with IgA deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Are there any clinical indications for measuring IgG subclasses?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Severity of infections in IgA deficiency: correlation with decreased serum antibodies to pneumococcal polysaccharides and decreased serum IgG2 and/or IgG4.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immunoglobulin G subclass deficiency: fact or fancy?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Clinical and immunologic characteristics of healthy children with subnormal serum concentrations of IgG2

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Therapy for patients with recurrent infections and low serum IgG3 levels

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Recurrent infections with IgG2 deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immunodeficiency presenting as hypergammaglobulinaemia with IgG2 subclass deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Selective IgG1 deficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

The Wiskott-Aldrich syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

IgG2 deficiency in children with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immunoglobulin class and subclass concentrations after treatment of childhood leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

An immunodeficiency characterized by impaired antibody responses to polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Selective defect in the antibody response to Haemophilus influenzae type b in children with recurrent infections and normal serum IgG subclass levels

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

In vitro analysis of humoral immunity in antibody deficiency with normal immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Preimmunization and postimmunization pneumococcal antibody titers in children with recurrent infections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Distribution of primary immunodeficiency diseases diagnosed in a pediatric tertiary hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immunology in the pediatrician's office.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Antibody deficiency syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Assessment of the antibody response to pneumococcal vaccine in high-risk populations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Pneumococcal vaccine in normal children. Primary and secondary vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Humoral immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Streptococcal sepsis presenting as acute abdomen in a child with transient hypogammaglobulinemia of infancy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Transient hypogammaglobulinemia of infancy: clinical and immunologic features of 40 new cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Features of transient hypogammaglobulinaemia in infants screened for immunological abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Transient hypogammaglobulinemia of infancy: Review of the literature, clinical and immunologic features of 11 new cases, and long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Absent specific viral antibodies in patients with transient hypogammaglobulinemia of infancy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

The outcome of patients with hypogammaglobulinemia in infancy and early childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Deficiency of T helper cells in transient hypogammaglobulinemia of infancy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Functional defect of B lymphocytes in a patient with selective IgM deficiency associated with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Selective IgM deficiency: functional assessment of peripheral blood lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Familial IgE deficiency associated with sinopulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Genetic dissection of immunity to mycobacteria: the human model

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-gamma) pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Viral infections in interferon-gamma receptor deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

561del4 defines a novel small deletion hotspot in the interferon-gamma receptor 1 chain

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Partial Interferon‐γ Receptor Signaling Chain Deficiency in a Patient with Bacille Calmette‐Guérin andMycobacterium abscessusInfection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

MYCOBACTERIUM FORTUITUM-CHELONAE COMPLEX INFECTION IN A CHILD WITH COMPLETE INTERLEUKIN-12 RECEPTOR BETA 1 DEFICIENCY

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Missense mutation of the interleukin-12 receptor beta1 chain-encoding gene is associated with impaired immunity against Mycobacterium avium complex infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Genetic variations in the interleukin-12/interleukin-23 receptor (beta1) chain, and implications for IL-12 and IL-23 receptor structure and function

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

High levels of interferon gamma in the plasma of children with complete interferon gamma receptor deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immunotherapy of mycobacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

The genetic background of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy and its autoimmune disease components

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Population genetics and functions of the autoimmune regulator (AIRE).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Cloning of the APECED gene provides new insight into human autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Gene defect behind APECED: a new clue to autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A common and recurrent 13-bp deletion in the autoimmune regulator gene in British kindreds with autoimmune polyendocrinopathy type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Severe malabsorption in autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy syndrome successfully treated with immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Prophylaxis against herpesvirus infections in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Pneumocystis carinii in a patient with pulmonary sarcoidosis and idiopathic CD4+ T lymphocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Disseminated tuberculosis and idiopathic CD4+ T-lymphocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Idiopathic CD4+ T lymphocytopenia associated with disseminated flat warts and alopecia areata.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Pleural effusion due to Histoplasma capsulatum and idiopathic CD4 lymphocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Idiopathic CD4+ T-lymphocytopenia in a child with disseminated cryptococcosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Muscular-skeletal cryptococcosis in a patient with idiopathic CD4+ lymphopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Active intestinal tuberculosis with esophageal candidiasis due to idiopathic CD4(+) T-lymphocytopenia in an elderly woman

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Cutaneous infections by papillomavirus, herpes zoster and Candida albicans as the only manifestation of idiopathic CD4+ T lymphocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Successful IL-2 therapy for relapsing herpes zoster infection in a patient with idiopathic CD4+ T lymphocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Idiopathic CD4+ lymphocytopenia and systemic vasculitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Idiopathic CD4+ T lymphocytopenia presenting as progressive multifocal leukoencephalopathy: case report.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Progressive multifocal leukoencephalopathy and idiopathic CD4+lymphocytopenia: a case report and review of reported cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Idiopathic CD4+ T-cell lymphocytopenia and subacute inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Idiopathic CD4+T-cell lymphocytopenia associated with vitiligo

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Idiopathic CD4+ T-lymphocytopenia with opportunistic infection and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Idiopathic CD4+ T lymphocytopenia in a patient with mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. An investigation of cases in the United States. The Centers for Disease Control Idiopathic CD4+ T-lymphocytopenia Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Idiopathic CD4+ T-lymphocytopenia--immunodeficiency without evidence of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Idiopathic CD4+ T-lymphocytopenia--an analysis of five patients with unexplained opportunistic infections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Idiopathic CD4+ T-lymphocytopenia--four patients with opportunistic infections and no evidence of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Idiopathic CD4+ T-Lymphocytopenia in an Asymptomatic HIV-Seronegative Woman after Exposure to HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Adenosine deaminase (ADA) deficiency as the unexpected cause of CD4+ T-lymphocytopenia in two HIV-negative adult female siblings

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Treatment of idiopathic CD4 T lymphocytopenia with IL-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Chronic mucocutaneous candidiasis in childhood and complications of non-Candida infection: a report of the Pediatric Immunodeficiency Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Chronic mucocutaneous candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

New perspectives on the immunology of chronic mucocutaneous candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Chronic mucocutaneous candidiasis. I. Altered antigen-stimulated IL-2, IL-4, IL-6 and interferon-gamma (IFN-gamma) production

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Chronic mucocutaneous candidiasis. II. Class and subclass of specific antibody responses in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Characterization of the cellular immune function of patients with chronic mucocutaneous candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Severe herpesvirus infections in an adolescent without natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Strong alpha beta and gamma delta TCR response in a patient with disseminated Mycobacterium avium infection and lack of NK cells and monocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A patient with simultaneous absence of "classical" natural killer cells (CD3-, CD16+, and NKH1+) and expansion of CD3+, CD4-, CD8-, NKH1+ subset.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A non-X-linked syndrome with susceptibility to severe epstein-barr virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Analysis of natural killer cells in TAP2-deficient patients: expression of functional triggering receptors and evidence for the existence of inhibitory receptor(s) that prevent lysis of normal autologous cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A boy with X-linked hyper-IgM syndrome and natural killer cell deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Deficiency in circulating natural killer (NK) cell subsets in common variable immunodeficiency and X-linked agammaglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

T-lymphocyte differentiation in severe combined immunodeficiency: Defects of the thymus

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Unexpected and variable phenotypes in a family with JAK3 deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Human IL-2 receptor alpha chain deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

RAG mutations in human B cell-negative SCID.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Omenn's syndrome: differential diagnosis in infants with erythroderma and immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

When the Lymphocyte Loses Its Clothes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

MHC class II deficiency: a disease of gene regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

TAP deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A subject with a novel type I bare lymphocyte syndrome has tapasin deficiency due to deletion of 4 exons by Alu-mediated recombination

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A mutation in zap-70 protein tyrosine kinase results in a selective immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutations in purine nucleoside phosphorylase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A deletion in the gene encoding the CD45 antigen in a patient with SCID.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Atypical X-Linked Severe Combined Immunodeficiency Due to Possible Spontaneous Reversion of the Genetic Defect in T Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Transplacentally acquired maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Gene therapy put on hold as third child develops cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A multiinstitutional survey of the Wiskott-Aldrich syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

X-linked Wiskott-Aldrich syndrome in a girl

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Flow cytometric determination of intracytoplasmic Wiskott-Aldrich syndrome protein in peripheral blood lymphocyte subpopulations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Clinical course of patients with WASP gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

WASP (Wiskott-Aldrich syndrome protein) gene mutations and phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Significant and persistent improvement of thrombocytopenia after splenectomy in an adult with the Wiskott-Aldrich Syndrome and intra-cerebral bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Consequences of the delayed diagnosis of ataxia-telangiectasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immunodeficiency and infections in ataxia-telangiectasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Nijmegen breakage syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Growth retardation and immunodeficiency in a patient with mutations in the DNA ligase I gene

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Oligo-/monoclonal gammopathy and hypergammaglobulinemia in ataxia-telangiectasia. A study of 90 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

IgG2 deficiency in ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Impaired IgG antibody production to pneumococcal polysaccharides in patients with ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Deficiencies in CD4+ and CD8+ T cell subsets in ataxia telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Relative increase of T cells expressing the gamma/delta rather than the alpha/beta receptor in ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

High frequency of spontaneous translocations revealed by FISH in cells from patients with the cancer-prone syndromes ataxia telangiectasia and Nijmegen breakage syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutations in the DNA ligase I gene of an individual with immunodeficiencies and cellular hypersensitivity to DNA-damaging agents

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Lymphoid malignancy as a presenting sign of ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Plasma levels of carcinoembryonic antigen in patients with ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Serum-alpha-fetoprotein levels in patients with ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Cutaneous granulomas as a presenting sign in ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Pigmentary anomalies in ataxia--telangiectasia: a clue to diagnosis and an example of twin spotting

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A late onset variant of ataxia-telangiectasia with a compound heterozygous genotype, A8030G/7481insA.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Granulomatous skin lesions in a patient with ataxia telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Genotype-phenotype relationships in ataxia-telangiectasia and variants.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Treatment of lymphoid malignancies in patients with ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Treatment of lymphoid malignancies in patients with ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Hodgkin disease in ataxia-telangiectasia patients with poor outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Modified chop-chemotherapy plus rituximab for diffuse large b-cell lymphoma complicating ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Ataxia telangiectasia and lymphoma: an indication for individualized chemotherapy dosing--report of treatment in a highly inbred Arab family

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

DiGeorge/velocardiofacial syndrome: FISH studies of chromosomes 22q11 and 10p14, and clinical reports on the proximal 22q11 deletion

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Chromosome 22q11.2 deletion syndrome (DiGeorge and velocardiofacial syndromes).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Role of TBX1 in human del22q11.2 syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

DiGeorge's syndrome: a gene at last

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Features of DiGeorge syndrome and CHARGE association in five patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Severe laryngomalacia and bronchomalacia in DiGeorge syndrome and CHARGE association

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Long-term assessment of T-cell populations in DiGeorge syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Transplantation of thymus tissue in complete DiGeorge syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immune constitution of complete DiGeorge anomaly by transplantation of unmobilised blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Clinical spectrum of X-linked hyper-IgM syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Defective antigen-induced lymphocyte proliferation in the X-linked hyper-IgM syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

CD40 ligand mutants responsible for X-linked hyper-IgM syndrome associate with wild type CD40 ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Development of a rapid whole blood flow cytometry procedure for the diagnosis of X-linked hyper-IgM syndrome patients and carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Absence of platelet CD40L identifies patients with X-linked hyper IgM syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Relapse of sclerosing cholangitis after liver transplant in patients with hyper-Ig M syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

X-linked lymphoproliferative syndrome registry report

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

X-linked lymphoproliferative disease is caused by deficiency of a novel SH2 domain-containing signal transduction adaptor protein

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

X-linked lymphoproliferative disease: three atypical cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutations of the X-linked lymphoproliferative disease gene SH2D1A mimicking common variable immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Detection of primary epstein-barr virus infection in a patient with x-linked lymphoproliferative disease receiving immunoglobulin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Clinical features of myelokathexis and treatment with hematopoietic cytokines: a case report of two patients and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKK-gamma)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Osteopetrosis, lymphedema, anhidrotic ectodermal dysplasia, and immunodeficiency in a boy and incontinentia pigmenti in his mother.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Incontinentia pigmenti in a surviving male is accompanied by hypohidrotic ectodermal dysplasia and recurrent infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Pyogenic bacterial infections in humans with IRAK-4 deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Phagocyte immunodeficiencies and their infections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Chronic granulomatous disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Incidence, severity, and prevention of infections in chronic granulomatous disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Itraconazole to prevent fungal infections in chronic granulomatous disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Successful treatment of invasive aspergillosis in chronic granulomatous disease by granulocyte transfusions followed by peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Primary phagocytic disorders of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Bone marrow transplantation for chronic granulomatous disease: long-term follow-up and review of literature

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

The role of high dose methylprednisolone and splenectomy in the accelerated phase of Chédiak-Higashi syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Partial albinism with immunodeficiency: Griscelli syndrome: report of a case and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Griscelli disease: genotype-phenotype correlation in an array of clinical heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Lytic granules, secretory lysosomes and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A rare syndrome in the differential diagnosis of hepatosplenomegaly and pancytopenia: report of identical twins with Griscelli disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Successful treatment of Griscelli syndrome with unrelated donor allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving beta 2 integrins and selectin ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Leukocyte adhesion deficiency II-from A to almost Z.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

The Severe and Moderate Phenotypes of Heritable Mac-1, LFA-1 Deficiency: Their Quantitative Definition and Relation to Leukocyte Dysfunction and Clinical Features

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Leukocyte adhesion deficiency (LAD) type II/carbohydrate deficient glycoprotein (CDG) IIc founder effect and genotype/phenotype correlation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A novel syndrome of variant leukocyte adhesion deficiency involving defects in adhesion mediated by beta1 and beta2 integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

A novel point mutation in CD18 causing the expression of dysfunctional CD11/CD18 leucocyte integrins in a patient with leucocyte adhesion deficiency (LAD)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Leukocyte adhesion deficiency type 1 (LAD-1)/variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Inherited Neutrophil Disorders: Molecular Basis and New Therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

1 reference

7 January 2021

Kostmann syndrome and severe congenital neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Staphylococcal IgE Antibodies, Hyperimmunoglobulinemia E andStaphylococcus aureusInfections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Whole organisms and purified cell walls compared as immunosorbents for the detection of IgE antibodies to Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Genetic linkage of hyper-IgE syndrome to chromosome 4.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

High-dose intravenous gamma-globulin treatment for hyperimmunoglobulinemia E syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Regulation of immunoglobulin production in hyperimmunoglobulin E recurrent-infection syndrome by interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Bone marrow transplantation does not correct the hyper IgE syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Navigating the maze of complement genetics: a guide for clinicians

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Complement Components, Complement Activation, and Acute Phase Response in Systemic Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Immunology of systemic rheumatoid disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mixed cryoglobulinaemia, glomerulonephritis, and ANCA: essential cryoglobulinaemic vasculitis or ANCA-associated vasculitis?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Complement deficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Diffuse crescentic glomerulonephritis in bacterial endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Association of parvovirus B19 infection with acute glomerulonephritis in healthy adults: case report and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Complement. Second of two parts

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Mannan-binding lectin insufficiency in children with recurrent infections of the respiratory system

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Complement. First of two parts

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

The role of complement in inflammation and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Familial and recurrent forms of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Complement factor H and the haemolytic uraemic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Subcutaneous immunoglobulins: Alternative for the hypogammaglobulinemic patient?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Increased risk of adverse events when changing intravenous immunoglobulin preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

IgA anaphylactic transfusion reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Acute renal failure in acquired haemophilia following the use of high dose intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

Nephrotoxicity of intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961142-8

7 January 2021

10.1016/S1081-1206(10)61142-8

Identifiers

DOI

2 references

https://doi.org/10.1016%2FS1081-1206%2810%2961142-8

27 March 2017

Consolidated OpenCitations Corpus – April 2017

3230869

3230869

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference